Raphael Pharmaceutical Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Raphael Pharmaceutical Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.28M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.52M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.34M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.36M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.63M) | May 25, 2023 |
| FY2021 | Dec 31, 2020 | ($718.0K) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.25M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.51M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.33M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.32M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.63M) | May 25, 2023 |
| FY2021 | Dec 31, 2020 | ($706.0K) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $631.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $776.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $569.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.18M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $776.0K | May 25, 2023 |
| FY2021 | Dec 31, 2020 | $461.0K | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($210.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($532.0K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($759.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.42M) | May 25, 2023 |
| FY2021 | Dec 31, 2020 | ($779.0K) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $2.0K | Mar 28, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $27.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $239.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $333.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $422.0K | May 25, 2023 |
| FY2021 | Dec 31, 2020 | $323.0K | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.43M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($742.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $107.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $106.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $128.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($43.0K) | May 25, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.17M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.89M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.37M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.03M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.67M) | May 25, 2023 |
| FY2021 | Dec 31, 2020 | ($1.04M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $19.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $230.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $288.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $153.0K | May 25, 2023 |
| FY2021 | Dec 31, 2020 | $95.0K | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | May 25, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | May 25, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 18.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 18.50M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 15.62M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 12.97M | May 25, 2023 |
| FY2023 | May 14, 2021 | 100 | Mar 28, 2024 |
| FY2021 | Dec 31, 2020 | 9.46M | Mar 30, 2022 |